Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.11M | 13.78M | 12.46M | 9.65M | 8.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.11M | 13.78M | 12.46M | 9.65M | 8.75M |
| Cost of Revenue | 570.00K | 1.76M | 660.00K | 967.00K | 373.00K |
| Gross Profit | 14.54M | 12.01M | 11.80M | 8.69M | 8.38M |
| SG&A Expenses | 14.61M | 14.55M | 11.96M | 11.31M | 9.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.23M | 16.33M | 12.65M | 12.38M | 9.56M |
| Operating Income | -119.00K | -2.55M | -189.00K | -2.73M | -808.00K |
| Income Before Tax | 201.00K | -4.68M | -638.00K | -3.15M | -1.17M |
| Income Tax Expenses | -- | 106.00K | -- | -- | -- |
| Earnings from Continuing Operations | 201.00K | -4.79M | -638.00K | -3.15M | -1.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 201.00K | -4.79M | -638.00K | -3.15M | -1.17M |
| EBIT | -119.00K | -2.55M | -189.00K | -2.73M | -808.00K |
| EBITDA | -93.00K | -2.53M | -163.00K | -2.71M | -782.00K |
| EPS Basic | 0.01 | -0.15 | -0.02 | -0.11 | -0.04 |
| Normalized Basic EPS | 0.00 | -0.05 | -0.01 | -0.07 | -0.03 |
| EPS Diluted | 0.01 | -0.15 | -0.02 | -0.11 | -0.04 |
| Normalized Diluted EPS | 0.00 | -0.05 | -0.01 | -0.07 | -0.03 |
| Average Basic Shares Outstanding | 34.34M | 31.18M | 27.89M | 27.66M | 27.58M |
| Average Diluted Shares Outstanding | 35.55M | 31.18M | 27.89M | 27.66M | 27.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |